• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感染世界性HTLV-I的患者血清中不同的HTLV-I中和模式。

Different HTLV-I neutralization patterns among sera of patients infected with cosmopolitan HTLV-I.

作者信息

Blanchard S, Astier-Gin T, Moynet D, Edouard E, Guillemain B

机构信息

INSERM U328, Institut Bergonié, Université Victor Segalen-Bordeaux 2, France.

出版信息

Virology. 1998 May 25;245(1):90-8. doi: 10.1006/viro.1998.9139.

DOI:10.1006/viro.1998.9139
PMID:9614870
Abstract

To determine if sequence variations observed in cosmopolitan HTLV-I interfered with viral recognition by neutralizing antibodies, we evaluated the neutralization potential of sera from persons infected by HTLV-I of this clade selected for amino acid changes in their eny glycoproteins. Each serum was used to neutralize three previously described HTLV-I isolates, 2060, 2072, and 1010, that possess amino acid env sequences differing at several positions, one of them being located in the immunodominant and neutralizable domain (aa 187-199). The results obtained in syncytia and/or reporter gene inhibition assays showed that the neutralization pattern of the sera clearly differed and could be classified in three categories. Five sera completely neutralized the three viruses with an equivalent titer, two sera gave a maximum inhibition, with higher ID50 on the 2072 virus than on the 2060 or 1010 viruses, and three sera had a stronger neutralization potential toward the 1010 virus than toward the 2060 virus. One of these sera partially neutralized the virus produced by 2072 cells, whereas neutralizing antibodies in the other two recognized the neutralizable epitopes on the 1010 or 2072 viruses equally well. Identification of amino acid sequences involved in induction of neutralizing antibodies with different recognition capacities could help identify new neutralizable epitopes of HTLV-I envelope glycoproteins and to better define the component(s) of an effective vaccine.

摘要

为了确定在世界性HTLV-I中观察到的序列变异是否会干扰中和抗体对病毒的识别,我们评估了来自感染该进化枝HTLV-I的人群血清的中和潜力,这些人群的eny糖蛋白中存在氨基酸变化。每种血清用于中和三种先前描述的HTLV-I分离株,2060、2072和1010,它们的氨基酸env序列在几个位置存在差异,其中一个位于免疫显性和可中和结构域(氨基酸187-199)。在细胞融合和/或报告基因抑制试验中获得的结果表明,血清的中和模式明显不同,可分为三类。五种血清以等效效价完全中和了这三种病毒,两种血清产生了最大抑制,对2072病毒的ID50高于对2060或1010病毒的ID50,三种血清对1010病毒的中和潜力比对2060病毒更强。其中一种血清部分中和了2072细胞产生的病毒,而另外两种血清中的中和抗体对1010或2072病毒上的可中和表位的识别能力相当。鉴定参与诱导具有不同识别能力的中和抗体的氨基酸序列,有助于识别HTLV-I包膜糖蛋白的新的可中和表位,并更好地确定有效疫苗的成分。

相似文献

1
Different HTLV-I neutralization patterns among sera of patients infected with cosmopolitan HTLV-I.感染世界性HTLV-I的患者血清中不同的HTLV-I中和模式。
Virology. 1998 May 25;245(1):90-8. doi: 10.1006/viro.1998.9139.
2
Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.I型人类T细胞白血病病毒包膜gp46抗原上中和表位的鉴定及肽免疫诱导中和抗体
J Immunol. 1991 Jul 1;147(1):354-60.
3
Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.1型人类嗜T淋巴细胞病毒表面包膜糖蛋白氨基末端和羧基末端部分的序列变异可诱导特异性中和抗体。
AIDS Res Hum Retroviruses. 2001 Mar 1;17(4):337-48. doi: 10.1089/08892220150503708.
4
Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.嵌合合成肽,包含来自人类嗜T淋巴细胞病毒I型(HTLV-I)包膜糖蛋白gp46和跨膜糖蛋白gp21的两个免疫显性表位。
Biochem Biophys Res Commun. 2001 Nov 23;289(1):1-6. doi: 10.1006/bbrc.2001.5821.
5
Variable and conserved neutralization antigens of human immunodeficiency virus.人类免疫缺陷病毒的可变中和抗原与保守中和抗原
Nature. 1986;324(6097):572-5. doi: 10.1038/324572a0.
6
Cross-neutralizing antibodies against cosmopolitan and Melanesian strains of human T cell leukemia/lymphotropic virus type I in sera from inhabitants of Africa and the Solomon Islands.来自非洲和所罗门群岛居民血清中针对人T细胞白血病/淋巴瘤病毒I型的世界性和美拉尼西亚菌株的交叉中和抗体。
AIDS Res Hum Retroviruses. 1994 Jan;10(1):91-6. doi: 10.1089/aid.1994.10.91.
7
Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies.人类1型T细胞白血病病毒表面糖蛋白第173位和187位的氨基酸变化可诱导特异性中和抗体。
J Virol. 1999 Nov;73(11):9369-76. doi: 10.1128/JVI.73.11.9369-9376.1999.
8
Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.来自血清具有广泛交叉反应中和活性的1型人类免疫缺陷病毒感染供体的包膜糖蛋白的中和及感染性特征。
Virology. 2006 Mar 30;347(1):36-51. doi: 10.1016/j.virol.2005.11.019. Epub 2005 Dec 27.
9
Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.用人嗜T淋巴细胞病毒I型(HTLV-I)血清阳性血清鉴定HTLV-I包膜糖蛋白的新型中和诱导区域
AIDS Res Hum Retroviruses. 1994 Feb;10(2):163-73. doi: 10.1089/aid.1994.10.163.
10
Expression of HTLV-I Env and Tax recombinant peptides in yeast: identification of immunogenic domains.人嗜T淋巴细胞病毒I型包膜糖蛋白和反式激活因子重组肽在酵母中的表达:免疫原性结构域的鉴定
Virology. 1993 Mar;193(1):80-8. doi: 10.1006/viro.1993.1105.

引用本文的文献

1
Conservation of a Neutralization Epitope of Human T-cell Leukemia Virus Type 1 (HTLV-1) among Currently Endemic Clinical Isolates in Okinawa, Japan.日本冲绳目前流行的人类T细胞白血病病毒1型(HTLV-1)临床分离株中中和表位的保守性
Pathogens. 2020 Jan 27;9(2):82. doi: 10.3390/pathogens9020082.
2
High variability of HTLV-I in a remote population of Gabon as compared to that of a similar population of French Guiana.与法属圭亚那的类似人群相比,加蓬偏远地区人群中HTLV-I的高变异性。
Virus Genes. 2001 Dec;23(3):257-61. doi: 10.1023/a:1012513121028.
3
Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies.
人类1型T细胞白血病病毒表面糖蛋白第173位和187位的氨基酸变化可诱导特异性中和抗体。
J Virol. 1999 Nov;73(11):9369-76. doi: 10.1128/JVI.73.11.9369-9376.1999.